FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ)
Identifieur interne : 001217 ( Main/Exploration ); précédent : 001216; suivant : 001218FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ)
Auteurs : C. O. Bingham [États-Unis] ; W. Rizzo ; M. Klearman [États-Unis] ; A. Hassanali [États-Unis] ; R. Upmanyu [Royaume-Uni] ; A. Kivitz [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Additional confounders, Amgen, Arthritis, Arthritis care, Brosis, Cardiovascular disease, Cholesterol levels, Cohort, Corrona, Corrona registry, Crescendo bioscience, Disease activity, Expert physician, Herpes zoster, Hrct, Hrct scores, Lung ultrasound, Nbio, Ntnfi, Ntnfi cohort, Positive response, Preliminary analysis, Propensity, Propensity score, Respiratory infection, Rheumatoid, Rheumatoid arthritis, Serotype combinations, Serum amyloid, Serum antibody titres, Serum samples, Synthetic disease, Tnfi, Tnfi cohort, Total number.
Abstract
Background TCZ is an IL-6-receptor signalling inhibitor licensed for use in RA. Because TCZ may impact how IL-6 affects T-cell activation and B-cell differentiation, response of TCZ-treated pts to vaccination is of interest. Data from small studies suggest TCZ does not negatively affect response to vaccination; more data are needed. Objectives To evaluate effects of TCZ on response to 23-valent pneumococcal polysaccharide vaccine (23VPPV) and tetanus toxoid vaccine (TTV) in RA pts on MTX. Methods This is a preliminary analysis from VISARA, an ongoing, controlled, open-label study in RA pts who have inadequate response/intolerance to ≥1 anti-TNF agent. Pts were stratified by age and randomised (2:1) to TCZ 8 mg/kg IV every 4 wks + MTX (Active) or MTX only (Control) for 20 wks. Baseline (BL) serology samples were collected 3 wks after the first infusion, just before vaccination with 23VPPV and TTV. At 8 wks, anti-pneumococcal and anti-tetanus antibody titres were evaluated. Endpoints were proportion of pts with positive response (2-fold or >1 mg/L increase in serum antibody titres) to ≥6 of 12 23VPPV serotypes (Primary) and proportion with positive response (4-fold or ≥0.2 mg/L increase in serum antibody titres) to TTV (Secondary) at 5 wks post-vaccination. Results For this preliminary analysis, data are available for the first 74/91 enrolled pts and presented only for 61 pts who met the per-protocol criteria (i.e. received ≥1 dose of study medication and both vaccines, had available BL and 8-wk titre samples; no protocol violations). A numerically greater percentage of Control than Active pts responded to ≥6 of 12 23VPPV serotypes at wk 8 (65.0% [95% CI, 44.1-85.9%] vs 53.7% [95% CI, 38.4-68.9%]). Greater proportion of Control than Active pts responded to serotype combinations (from ≥1 to ≥12). However, there was a notable degree of variability between pts as reflected by wide CIs within both groups, particularly for the higher number of serotype combinations (graph). The percentage of responders to TTV was comparable between groups (Active [43.9%; 95% CI, 28.7-59.1%] vs Control [36.8%; 95% CI, 15.2-58.5%]). Conclusions Results suggest TCZ- and MTX-treated RA pts have comparable recall response to TTV, but response to 23VPPV is slightly reduced with TCZ. If possible, pneumococcal polysaccharide vaccination should be given before initiating TCZ to maximise response. These data are for 2 TCZ infusions and may only reflect initial effects of TCZ on the humoural immune response. Effects of long-term dosing are not addressed. Disclosure of Interest C. Bingham III Grant/Research support from: Roche/Genentech, Consultant for: Roche/Genentech, W. Rizzo Grant/Research support from: Advanced Arthritis Care and Research, Consultant for: UCB, Savient, Speakers Bureau: Amgen, Takeda, UCB, Roche, Abbott, M. Klearman Employee of: Roche/Genentech, A. Hassanali Employee of: Roche/Genentech, R. Upmanyu Employee of: Roche, A. Kivitz Speakers Bureau: Roche
Url:
DOI: 10.1136/annrheumdis-2012-eular.2563
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B12
- to stream Istex, to step Curation: 000B12
- to stream Istex, to step Checkpoint: 000269
- to stream Main, to step Merge: 001218
- to stream Main, to step Curation: 001217
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ)</title>
<author><name sortKey="Bingham, C O" sort="Bingham, C O" uniqKey="Bingham C" first="C. O." last="Bingham">C. O. Bingham</name>
</author>
<author><name sortKey="Rizzo, W" sort="Rizzo, W" uniqKey="Rizzo W" first="W." last="Rizzo">W. Rizzo</name>
</author>
<author><name sortKey="Klearman, M" sort="Klearman, M" uniqKey="Klearman M" first="M." last="Klearman">M. Klearman</name>
</author>
<author><name sortKey="Hassanali, A" sort="Hassanali, A" uniqKey="Hassanali A" first="A." last="Hassanali">A. Hassanali</name>
</author>
<author><name sortKey="Upmanyu, R" sort="Upmanyu, R" uniqKey="Upmanyu R" first="R." last="Upmanyu">R. Upmanyu</name>
</author>
<author><name sortKey="Kivitz, A" sort="Kivitz, A" uniqKey="Kivitz A" first="A." last="Kivitz">A. Kivitz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E21120B821E00A363DE72B54D2D849BAF25F1D0E</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.2563</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-CTR18Q4N-L/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B12</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B12</idno>
<idno type="wicri:Area/Istex/Curation">000B12</idno>
<idno type="wicri:Area/Istex/Checkpoint">000269</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000269</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Bingham C:fri:preliminary:results</idno>
<idno type="wicri:Area/Main/Merge">001218</idno>
<idno type="wicri:Area/Main/Curation">001217</idno>
<idno type="wicri:Area/Main/Exploration">001217</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ)</title>
<author><name sortKey="Bingham, C O" sort="Bingham, C O" uniqKey="Bingham C" first="C. O." last="Bingham">C. O. Bingham</name>
<affiliation wicri:level="3"><country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
<wicri:orgArea>Johns Hopkins U</wicri:orgArea>
</affiliation>
<affiliation wicri:level="3"><country>États-Unis</country>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
<wicri:orgArea>Johns Hopkins U</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Rizzo, W" sort="Rizzo, W" uniqKey="Rizzo W" first="W." last="Rizzo">W. Rizzo</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="subField">Scottsdale</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Klearman, M" sort="Klearman, M" uniqKey="Klearman M" first="M." last="Klearman">M. Klearman</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Genentech, South San Francisco</wicri:regionArea>
<wicri:noRegion>South San Francisco</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Genentech, South San Francisco</wicri:regionArea>
<wicri:noRegion>South San Francisco</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hassanali, A" sort="Hassanali, A" uniqKey="Hassanali A" first="A." last="Hassanali">A. Hassanali</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Genentech, South San Francisco</wicri:regionArea>
<wicri:noRegion>South San Francisco</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Genentech, South San Francisco</wicri:regionArea>
<wicri:noRegion>South San Francisco</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Upmanyu, R" sort="Upmanyu, R" uniqKey="Upmanyu R" first="R." last="Upmanyu">R. Upmanyu</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Roche, Welwyn</wicri:regionArea>
<wicri:noRegion>Welwyn</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Roche, Welwyn</wicri:regionArea>
<wicri:noRegion>Welwyn</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kivitz, A" sort="Kivitz, A" uniqKey="Kivitz A" first="A." last="Kivitz">A. Kivitz</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Altoona Arthritis Osteoporosis Ctr, Duncansville</wicri:regionArea>
<wicri:noRegion>Duncansville</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Altoona Arthritis Osteoporosis Ctr, Duncansville</wicri:regionArea>
<wicri:noRegion>Duncansville</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="345">345</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Additional confounders</term>
<term>Amgen</term>
<term>Arthritis</term>
<term>Arthritis care</term>
<term>Brosis</term>
<term>Cardiovascular disease</term>
<term>Cholesterol levels</term>
<term>Cohort</term>
<term>Corrona</term>
<term>Corrona registry</term>
<term>Crescendo bioscience</term>
<term>Disease activity</term>
<term>Expert physician</term>
<term>Herpes zoster</term>
<term>Hrct</term>
<term>Hrct scores</term>
<term>Lung ultrasound</term>
<term>Nbio</term>
<term>Ntnfi</term>
<term>Ntnfi cohort</term>
<term>Positive response</term>
<term>Preliminary analysis</term>
<term>Propensity</term>
<term>Propensity score</term>
<term>Respiratory infection</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Serotype combinations</term>
<term>Serum amyloid</term>
<term>Serum antibody titres</term>
<term>Serum samples</term>
<term>Synthetic disease</term>
<term>Tnfi</term>
<term>Tnfi cohort</term>
<term>Total number</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background TCZ is an IL-6-receptor signalling inhibitor licensed for use in RA. Because TCZ may impact how IL-6 affects T-cell activation and B-cell differentiation, response of TCZ-treated pts to vaccination is of interest. Data from small studies suggest TCZ does not negatively affect response to vaccination; more data are needed. Objectives To evaluate effects of TCZ on response to 23-valent pneumococcal polysaccharide vaccine (23VPPV) and tetanus toxoid vaccine (TTV) in RA pts on MTX. Methods This is a preliminary analysis from VISARA, an ongoing, controlled, open-label study in RA pts who have inadequate response/intolerance to ≥1 anti-TNF agent. Pts were stratified by age and randomised (2:1) to TCZ 8 mg/kg IV every 4 wks + MTX (Active) or MTX only (Control) for 20 wks. Baseline (BL) serology samples were collected 3 wks after the first infusion, just before vaccination with 23VPPV and TTV. At 8 wks, anti-pneumococcal and anti-tetanus antibody titres were evaluated. Endpoints were proportion of pts with positive response (2-fold or >1 mg/L increase in serum antibody titres) to ≥6 of 12 23VPPV serotypes (Primary) and proportion with positive response (4-fold or ≥0.2 mg/L increase in serum antibody titres) to TTV (Secondary) at 5 wks post-vaccination. Results For this preliminary analysis, data are available for the first 74/91 enrolled pts and presented only for 61 pts who met the per-protocol criteria (i.e. received ≥1 dose of study medication and both vaccines, had available BL and 8-wk titre samples; no protocol violations). A numerically greater percentage of Control than Active pts responded to ≥6 of 12 23VPPV serotypes at wk 8 (65.0% [95% CI, 44.1-85.9%] vs 53.7% [95% CI, 38.4-68.9%]). Greater proportion of Control than Active pts responded to serotype combinations (from ≥1 to ≥12). However, there was a notable degree of variability between pts as reflected by wide CIs within both groups, particularly for the higher number of serotype combinations (graph). The percentage of responders to TTV was comparable between groups (Active [43.9%; 95% CI, 28.7-59.1%] vs Control [36.8%; 95% CI, 15.2-58.5%]). Conclusions Results suggest TCZ- and MTX-treated RA pts have comparable recall response to TTV, but response to 23VPPV is slightly reduced with TCZ. If possible, pneumococcal polysaccharide vaccination should be given before initiating TCZ to maximise response. These data are for 2 TCZ infusions and may only reflect initial effects of TCZ on the humoural immune response. Effects of long-term dosing are not addressed. Disclosure of Interest C. Bingham III Grant/Research support from: Roche/Genentech, Consultant for: Roche/Genentech, W. Rizzo Grant/Research support from: Advanced Arthritis Care and Research, Consultant for: UCB, Savient, Speakers Bureau: Amgen, Takeda, UCB, Roche, Abbott, M. Klearman Employee of: Roche/Genentech, A. Hassanali Employee of: Roche/Genentech, R. Upmanyu Employee of: Roche, A. Kivitz Speakers Bureau: Roche</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
<settlement><li>Baltimore</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Rizzo, W" sort="Rizzo, W" uniqKey="Rizzo W" first="W." last="Rizzo">W. Rizzo</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Bingham, C O" sort="Bingham, C O" uniqKey="Bingham C" first="C. O." last="Bingham">C. O. Bingham</name>
</region>
<name sortKey="Bingham, C O" sort="Bingham, C O" uniqKey="Bingham C" first="C. O." last="Bingham">C. O. Bingham</name>
<name sortKey="Hassanali, A" sort="Hassanali, A" uniqKey="Hassanali A" first="A." last="Hassanali">A. Hassanali</name>
<name sortKey="Hassanali, A" sort="Hassanali, A" uniqKey="Hassanali A" first="A." last="Hassanali">A. Hassanali</name>
<name sortKey="Kivitz, A" sort="Kivitz, A" uniqKey="Kivitz A" first="A." last="Kivitz">A. Kivitz</name>
<name sortKey="Kivitz, A" sort="Kivitz, A" uniqKey="Kivitz A" first="A." last="Kivitz">A. Kivitz</name>
<name sortKey="Klearman, M" sort="Klearman, M" uniqKey="Klearman M" first="M." last="Klearman">M. Klearman</name>
<name sortKey="Klearman, M" sort="Klearman, M" uniqKey="Klearman M" first="M." last="Klearman">M. Klearman</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Upmanyu, R" sort="Upmanyu, R" uniqKey="Upmanyu R" first="R." last="Upmanyu">R. Upmanyu</name>
</noRegion>
<name sortKey="Upmanyu, R" sort="Upmanyu, R" uniqKey="Upmanyu R" first="R." last="Upmanyu">R. Upmanyu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001217 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001217 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E21120B821E00A363DE72B54D2D849BAF25F1D0E |texte= FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ) }}
This area was generated with Dilib version V0.6.33. |